Cargando…

Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment

AIM: Currently, there is no consensus on the retreatment recommendation of chronic hepatitis B (CHB) patients with viral rebound after cessation of treatment. In the search of reasonable treatment, we compared the efficacy and safety of adefovir (ADV) plus lamivudine (LAM) and LAM alone for the retr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhao, Wu, Xiao-Ling, Zeng, Wei-Zheng, Xu, Hui, Zhang, Yong, Qin, Jian-Ping, Jiang, Ming-De
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162546/
https://www.ncbi.nlm.nih.gov/pubmed/21816062
http://dx.doi.org/10.1186/1743-422X-8-388
_version_ 1782210826295312384
author Wang, Zhao
Wu, Xiao-Ling
Zeng, Wei-Zheng
Xu, Hui
Zhang, Yong
Qin, Jian-Ping
Jiang, Ming-De
author_facet Wang, Zhao
Wu, Xiao-Ling
Zeng, Wei-Zheng
Xu, Hui
Zhang, Yong
Qin, Jian-Ping
Jiang, Ming-De
author_sort Wang, Zhao
collection PubMed
description AIM: Currently, there is no consensus on the retreatment recommendation of chronic hepatitis B (CHB) patients with viral rebound after cessation of treatment. In the search of reasonable treatment, we compared the efficacy and safety of adefovir (ADV) plus lamivudine (LAM) and LAM alone for the retreatment of patients with viral relapse but without genotypic resistance after cessation of LAM. METHODS: This is a prospective controlled study, and a total of 53 hepatitis B e antigen (HBeAg)-positive patients with viral rebound but without resistance were received either LAM plus ADV or LAM alone treatment. RESULTS: After 1-year treatment, more patients who received LAM plus ADV than those who received LAM alone had ALT normalization (84% versus 53.6%, P = 0.018) or HBV DNA levels below 1000 copies/mL (80% versus 42.9%, P < 0.006). Seven patients receiving LAM plus ADV had HBeAg seroconversion, as compared with 0 in patients receiving ALM alone (28% versus 0%, P = 0.003). During 1-year retreatment, five patients receiving LAM alone had virological breakthrough and all of them had LAM resistance strains (rtM204V/I), while no LAM- or ADV- associated resistance strains were detected in patients receiving LAM plus ADV. All patients receiving LAM plus ADV were well tolerated, and no serious side effects were noted. CONCLUSIONS: Patients treated with LAM plus ADV exhibited significantly greater virological, biochemical and serological responses compared with LAM alone. These data suggested that combination of LAM plus ADV would be a good option for the retreatment of CHB patients with viral relapse after cessation of LAM.
format Online
Article
Text
id pubmed-3162546
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31625462011-08-27 Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment Wang, Zhao Wu, Xiao-Ling Zeng, Wei-Zheng Xu, Hui Zhang, Yong Qin, Jian-Ping Jiang, Ming-De Virol J Research AIM: Currently, there is no consensus on the retreatment recommendation of chronic hepatitis B (CHB) patients with viral rebound after cessation of treatment. In the search of reasonable treatment, we compared the efficacy and safety of adefovir (ADV) plus lamivudine (LAM) and LAM alone for the retreatment of patients with viral relapse but without genotypic resistance after cessation of LAM. METHODS: This is a prospective controlled study, and a total of 53 hepatitis B e antigen (HBeAg)-positive patients with viral rebound but without resistance were received either LAM plus ADV or LAM alone treatment. RESULTS: After 1-year treatment, more patients who received LAM plus ADV than those who received LAM alone had ALT normalization (84% versus 53.6%, P = 0.018) or HBV DNA levels below 1000 copies/mL (80% versus 42.9%, P < 0.006). Seven patients receiving LAM plus ADV had HBeAg seroconversion, as compared with 0 in patients receiving ALM alone (28% versus 0%, P = 0.003). During 1-year retreatment, five patients receiving LAM alone had virological breakthrough and all of them had LAM resistance strains (rtM204V/I), while no LAM- or ADV- associated resistance strains were detected in patients receiving LAM plus ADV. All patients receiving LAM plus ADV were well tolerated, and no serious side effects were noted. CONCLUSIONS: Patients treated with LAM plus ADV exhibited significantly greater virological, biochemical and serological responses compared with LAM alone. These data suggested that combination of LAM plus ADV would be a good option for the retreatment of CHB patients with viral relapse after cessation of LAM. BioMed Central 2011-08-04 /pmc/articles/PMC3162546/ /pubmed/21816062 http://dx.doi.org/10.1186/1743-422X-8-388 Text en Copyright ©2011 Wang et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Wang, Zhao
Wu, Xiao-Ling
Zeng, Wei-Zheng
Xu, Hui
Zhang, Yong
Qin, Jian-Ping
Jiang, Ming-De
Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
title Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
title_full Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
title_fullStr Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
title_full_unstemmed Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
title_short Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment
title_sort lamivudine plus adefovir is a good option for chronic hepatitis b patients with viral relapse after cessation of lamivudine treatment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162546/
https://www.ncbi.nlm.nih.gov/pubmed/21816062
http://dx.doi.org/10.1186/1743-422X-8-388
work_keys_str_mv AT wangzhao lamivudineplusadefovirisagoodoptionforchronichepatitisbpatientswithviralrelapseaftercessationoflamivudinetreatment
AT wuxiaoling lamivudineplusadefovirisagoodoptionforchronichepatitisbpatientswithviralrelapseaftercessationoflamivudinetreatment
AT zengweizheng lamivudineplusadefovirisagoodoptionforchronichepatitisbpatientswithviralrelapseaftercessationoflamivudinetreatment
AT xuhui lamivudineplusadefovirisagoodoptionforchronichepatitisbpatientswithviralrelapseaftercessationoflamivudinetreatment
AT zhangyong lamivudineplusadefovirisagoodoptionforchronichepatitisbpatientswithviralrelapseaftercessationoflamivudinetreatment
AT qinjianping lamivudineplusadefovirisagoodoptionforchronichepatitisbpatientswithviralrelapseaftercessationoflamivudinetreatment
AT jiangmingde lamivudineplusadefovirisagoodoptionforchronichepatitisbpatientswithviralrelapseaftercessationoflamivudinetreatment